Complete details of the Request for Proposals issued on August 3, 2018, can be found in the PDF posted on the Blavatnik Biomedical Accelerator's webpage for Harvard faculty:

Learn More

Please contact .(JavaScript must be enabled to view this email address) with any questions.

Application timeline, Fall 2018 cycle

Application type: Pilot applications
Pre-proposal due date: September 11, 2018
Announcement of finalists: October 2018
Full proposal due date: November 20, 2018
Announcement of awards: December 2018
Funding start date: January 1, 2019

NOTE: Applications are also being accepted for the Spring 2019 cycle (funding beginning on July 1, 2019), for both Development and Pilot grants. The deadline for pre-proposals in that cycle is November 27, 2018.

About the Blavatnik Biomedical Accelerator

The Blavatnik Biomedical Accelerator at Harvard University supports Harvard faculty in the performance and commercialization of applied life sciences research.

The Accelerator has provided $18.5 million in direct research support to 103 projects from across Harvard University targeting most major disease areas, including oncology, metabolic disease, diabetes, immuno-inflammatory disease, infectious diseases, and neurodegeneration. Supported projects have included therapeutics, diagnostics/biomarkers, instruments, and other biomedical technologies. Nearly half of all completed projects have been partnered with industry, through licenses to pharmaceutical, biotech, and startup firms (some launched from the Accelerator-supported technology) or via major industry-sponsored research agreements. These alliances have also led to more than $38 million in follow-on industry-sponsored research funding. The Accelerator is structured as a sustainable, “evergreen” program, with revenue from successfully launched technologies cycled back to support ongoing and future Accelerator projects.

The Accelerator and its funded projects are managed by the Office of Technology Development (OTD) under the auspices of the Office of the Provost, in consultation with an independent advisory committee comprising leaders from the Boston life science community.